BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 23034282)

  • 21. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
    Jardin F; Pujals A; Pelletier L; Bohers E; Camus V; Mareschal S; Dubois S; Sola B; Ochmann M; Lemonnier F; Viailly PJ; Bertrand P; Maingonnat C; Traverse-Glehen A; Gaulard P; Damotte D; Delarue R; Haioun C; Argueta C; Landesman Y; Salles G; Jais JP; Figeac M; Copie-Bergman C; Molina TJ; Picquenot JM; Cornic M; Fest T; Milpied N; Lemasle E; Stamatoullas A; Moeller P; Dyer MJ; Sundstrom C; Bastard C; Tilly H; Leroy K
    Am J Hematol; 2016 Sep; 91(9):923-30. PubMed ID: 27312795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
    Lucas F; Rogers KA; Harrington BK; Pan A; Yu L; Breitbach J; Bundschuh R; Goettl VM; Hing ZA; Kanga P; Mantel R; Sampath D; Smith LL; Wasmuth R; White DK; Yan P; Byrd JC; Lapalombella R; Woyach JA
    Clin Cancer Res; 2019 Oct; 25(20):6260-6273. PubMed ID: 31296529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 25. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.
    Neggers JE; Vercruysse T; Jacquemyn M; Vanstreels E; Baloglu E; Shacham S; Crochiere M; Landesman Y; Daelemans D
    Chem Biol; 2015 Jan; 22(1):107-16. PubMed ID: 25579209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
    J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.
    Inoue H; Kauffman M; Shacham S; Landesman Y; Yang J; Evans CP; Weiss RH
    J Urol; 2013 Jun; 189(6):2317-26. PubMed ID: 23079374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XPO1-dependent nuclear export as a target for cancer therapy.
    Azizian NG; Li Y
    J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystallization of Nuclear Export Signals or Small-Molecule Inhibitors Bound to Nuclear Exporter CRM1.
    Fung HYJ; Chook YM
    Methods Mol Biol; 2022; 2502():285-297. PubMed ID: 35412246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
    Gerecitano J
    J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.
    Taylor J; Sendino M; Gorelick AN; Pastore A; Chang MT; Penson AV; Gavrila EI; Stewart C; Melnik EM; Herrejon Chavez F; Bitner L; Yoshimi A; Lee SC; Inoue D; Liu B; Zhang XJ; Mato AR; Dogan A; Kharas MG; Chen Y; Wang D; Soni RK; Hendrickson RC; Prieto G; Rodriguez JA; Taylor BS; Abdel-Wahab O
    Cancer Discov; 2019 Oct; 9(10):1452-1467. PubMed ID: 31285298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.
    Azmi AS; Al-Katib A; Aboukameel A; McCauley D; Kauffman M; Shacham S; Mohammad RM
    Haematologica; 2013 Jul; 98(7):1098-106. PubMed ID: 23403316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
    Schmidt J; Braggio E; Kortuem KM; Egan JB; Zhu YX; Xin CS; Tiedemann RE; Palmer SE; Garbitt VM; McCauley D; Kauffman M; Shacham S; Chesi M; Bergsagel PL; Stewart AK
    Leukemia; 2013 Dec; 27(12):2357-65. PubMed ID: 23752175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.
    Wang S; Sellner L; Wang L; Sauer T; Neuber B; Gong W; Stock S; Ni M; Yao H; Kleist C; Schmitt A; Müller-Tidow C; Schmitt M; Schubert ML
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34165175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting XPO1-Dependent Nuclear Export in Cancer.
    Kim E; Mordovkina DA; Sorokin A
    Biochemistry (Mosc); 2022 Jan; 87(Suppl 1):S178-S70. PubMed ID: 35501995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
    Niu M; Chong Y; Han Y; Liu X
    Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies.
    Allegra A; Innao V; Allegra AG; Leanza R; Musolino C
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):689-698. PubMed ID: 31543372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.